Anterior ischemic optic neuropathy is a sudden loss of vision due to poor blood flow to the optic nerve. People with anterior ischemic optic neuropathy often notice painless vision loss in one eye, with dim or missing areas and reduced color vision. It can occur at any age but is more common after age 50, and risk is higher with high blood pressure, diabetes, or sleep apnea. Treatment focuses on protecting the other eye and managing risks, and high-dose steroids are used when giant cell arteritis is suspected. The outlook varies, but prompt care can lower the chance of further vision loss.
Overview
Anterior ischemic optic neuropathySymptoms
Anterior ischemic optic neuropathy causes sudden, painless vision loss in one eye, often first noticed on waking. People describe a dark shadow or missing area and colors looking washed out. Early symptoms may include dim, blurry, or patchy sight.
Outlook and prognosis
Many living with anterior ischemic optic neuropathy notice sudden vision loss that often stabilizes over weeks; some recover part of their sight, usually within the first 3–6 months. The fellow eye can be at risk, especially with untreated vascular factors. Managing blood pressure, diabetes, sleep apnea, and avoiding nocturnal low blood pressure may lower that risk and support overall eye health.
Causes and risk factors
Anterior ischemic optic neuropathy usually follows reduced optic-nerve blood flow from giant cell arteritis or small-vessel disease. Risk factors include older age, hypertension, diabetes, sleep apnea, smoking, plus inherited crowded optic discs and genetic susceptibility to vasculitis, and certain medicines.
Genetic influences
Genetics play a modest role in anterior ischemic optic neuropathy. Most cases relate to vascular risk factors, but inherited traits like crowded optic discs or blood clotting tendencies can increase susceptibility. Rarely, mitochondrial or small-vessel gene variants may contribute.
Diagnosis
Diagnosis of anterior ischemic optic neuropathy is based on sudden vision loss and eye exam findings, including optic disc changes and visual field testing. OCT or fluorescein angiography can help. ESR/CRP screen for giant cell arteritis; temporal artery biopsy confirms.
Treatment and drugs
Treatment for anterior ischemic optic neuropathy focuses on protecting the other eye and supporting vision. Care may include prompt evaluation, managing blood pressure, diabetes, and sleep apnea, treating giant cell arteritis with steroids, and using low-vision aids and rehabilitation.
Symptoms
Vision changes from anterior ischemic optic neuropathy often come on suddenly and are usually painless. Some early symptoms of anterior ischemic optic neuropathy include blurred or dim vision in one eye, a missing patch in your field of view, and colors looking less vivid, sometimes noticed on waking. Symptoms vary from person to person and can change over time.
Vision in one eye may drop over minutes to hours, often without warning. The change is usually painless and not complete blackout. Many notice it most when covering the other eye.
Many people notice the change first thing in the morning. This has been reported in anterior ischemic optic neuropathy and can make the room look dim or hazy. If it develops during the day, it often stabilizes within hours.
Sight can look foggy or washed out, especially in low light. Reading or recognizing faces may take extra effort.
Part of the upper or lower view may seem gone, like a shadow or curtain. You might bump into objects on the affected side.
How people usually first notice Anterior ischemic optic neuropathy?
Many people first notice anterior ischemic optic neuropathy when they wake up with sudden, painless vision loss in one eye, often described as a dark shadow or curtain in part of their visual field. Colors may look dimmer, and reading or noticing objects on one side becomes harder, prompting an urgent eye exam where a doctor may see a swollen, pale optic disc. For some, especially those over 50 with headaches, scalp tenderness, or jaw pain from giant cell arteritis, the first signs of AION include these systemic symptoms followed by rapid vision changes, which is a medical emergency.
Types of Anterior ischemic optic neuropathy
Anterior ischemic optic neuropathy (AION) has more than one form, and the type often guides urgency and treatment. Broadly, symptoms are grouped into forms linked to inflamed arteries versus those that are not. This helps explain why some people have sudden vision loss with scalp tenderness and jaw pain, while others have a painless, isolated event. Not everyone will experience every type.
Arteritic AION
This form is tied to inflamed blood vessels, most often due to giant cell arteritis, and can threaten vision in both eyes quickly. People may notice sudden, painless vision loss along with new headache, scalp tenderness, or jaw pain when chewing.
Nonarteritic AION
This form is not caused by vessel inflammation and often happens in people with small, crowded optic nerves and vascular risk factors. Vision loss is sudden and usually painless, and it often affects one eye first.
Recurrent nonarteritic
Some people have more than one nonarteritic AION event over time, sometimes in the same eye or later in the other eye. The symptoms mirror nonarteritic AION, with additional impact from repeated episodes.
Perioperative AION
This occurs around the time of major surgery, such as lengthy spine or heart procedures, when blood pressure drops or blood loss is significant. Vision changes are typically sudden and painless after the operation.
Typical versus atypical
Doctors sometimes classify symptoms as typical versus atypical. Typical patterns fit well-known features of arteritic or nonarteritic AION, while atypical ones may prompt a broader workup for other optic nerve or eye conditions, helping distinguish types of AION.
What genetics can tell you about symptoms
Certain inherited changes in blood clotting or vessel structure can raise the risk of AION, leading to sudden, painless vision loss in one eye and trouble seeing in dim light. Variants like MTHFR, Factor V Leiden, and mitochondrial DNA changes may worsen optic nerve damage.
Causes and risk factors
Causes of anterior ischemic optic neuropathy center on reduced blood flow to the optic nerve, and there are arteritic and non-arteritic forms. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). In the arteritic form, an immune inflammation of the arteries called giant cell arteritis is the cause, and risk rises with age over 50 years. In the non-arteritic form, risks include high blood pressure, diabetes, high cholesterol, sleep apnea, smoking, and a small crowded optic nerve present from birth. Large drops in blood pressure at night, blood loss with surgery, or severe anemia can trigger an episode, which is why early symptoms of anterior ischemic optic neuropathy often follow waking.
Environmental and biological risk factors
Anterior ischemic optic neuropathy is a problem with blood flow to the front of the optic nerve that can cause sudden vision loss in one eye, which can disrupt reading or driving. Doctors often group risks into internal (biological) and external (environmental). Knowing these risks can help you act quickly if early symptoms of Anterior ischemic optic neuropathy appear.
Risk of anterior ischemic optic neuropathy rises with age, especially after 50. Aging vessels can deliver less steady blood flow to the optic nerve.
A small, crowded optic nerve head leaves little room for swelling. This anatomy raises the chance of anterior ischemic optic neuropathy.
Inflammation of medium and large arteries can abruptly cut blood supply to the optic nerve. This can cause anterior ischemic optic neuropathy and needs urgent treatment.
High blood pressure, diabetes, and high cholesterol can damage vessel linings over time. These changes raise the risk of anterior ischemic optic neuropathy.
Genetic risk factors
For anterior ischemic optic neuropathy, genes play a small but real role, mainly by shaping immune responses and optic nerve anatomy. Risk is not destiny—it varies widely between individuals. Knowing your background can prompt quicker checks if you notice early symptoms of anterior ischemic optic neuropathy.
Immune gene patterns: Inherited immune system variants raise the chance of giant cell arteritis, an inflammation that can trigger arteritic anterior ischemic optic neuropathy. These variants tend to run in families and some populations. They raise risk but don’t make vision loss inevitable.
Northern European ancestry: Certain immune gene patterns are more frequent in people with Northern European roots, increasing the likelihood of giant cell arteritis. This raises the chance of optic nerve damage from reduced blood flow. Individual risk still depends on your unique mix of genes.
Crowded optic disc: A small, crowded optic nerve head can be inherited and often appears in both eyes. Eye doctors can see this structural feature during a dilated exam. It raises the chance of the non-arteritic form of anterior ischemic optic neuropathy.
Optic disc drusen: Tiny deposits within the optic disc often run in families. They can compress nerve fibers and reduce blood-flow reserve, increasing susceptibility to ischemic damage. This can raise the chance of optic nerve injury.
Family history: Having a close relative with similar optic nerve problems suggests shared inherited traits, such as optic disc shape or immune tendencies. Familial clustering is uncommon but documented. Genetic testing is not routinely recommended to assess risk.
Lifestyle risk factors
Several day-to-day choices can alter blood flow and oxygen delivery to the optic nerve, influencing the chance of an episode and the risk to the other eye. The most important lifestyle risk factors for Anterior ischemic optic neuropathy are those that worsen small-vessel health or trigger drops in nighttime blood pressure. Addressing them may reduce the likelihood of first events and recurrences. Work with your clinician to tailor changes safely, especially around sleep, blood pressure, and medications.
Tobacco damages small blood vessels and reduces oxygen delivery to the optic nerve. Quitting lowers vascular strain and may reduce NAION risk.
Large drops in nighttime blood pressure can reduce optic nerve perfusion. Avoid over-aggressive late-evening BP lowering without medical guidance.
Poor glycemic control injures small vessels that feed the optic nerve. Diet and activity that improve A1c may lower NAION risk and fellow-eye involvement.
Diets high in saturated and trans fats raise LDL and promote atherosclerosis. Heart-healthy eating supports optic nerve blood flow.
Risk prevention
While you can’t always prevent anterior ischemic optic neuropathy (AION), lowering cardiovascular risks and acting quickly if vision changes can help protect sight, especially in the other eye. Prevention is about lowering risk, not eliminating it completely. For the arteritic form tied to giant cell arteritis, urgent treatment can be sight‑saving. Knowing early symptoms of anterior ischemic optic neuropathy and seeking same‑day care can make a real difference.
Keep blood pressure in a healthy range without letting it drop too low, especially at night. Ask your doctor about timing blood pressure pills to avoid big overnight dips.
Steady blood sugar helps protect small blood vessels that feed the optic nerve. Aim for consistent glucose control through food, activity, and medicines as advised.
Healthy cholesterol levels support better blood flow and reduce plaque buildup. Diet changes and, when needed, medications can lower risk over time.
Using CPAP or other prescribed treatments maintains oxygen levels during sleep. This helps prevent nighttime drops in blood pressure and oxygen that can strain the optic nerve.
Transmission
Anterior ischemic optic neuropathy (AION) is not contagious and cannot be transferred from one person to another. It also isn’t considered an inherited eye disease; most cases come from a sudden drop in blood flow to the optic nerve linked to age and vascular risk factors, not from a gene change passed down in families. Even in arteritic anterior ischemic optic neuropathy caused by giant cell arteritis, the problem does not spread between people. If several relatives are affected, it usually reflects shared health risks or optic nerve anatomy, not genetic transmission.
When to test your genes
Consider genetic testing if AION appears unusually early, runs in your family, or occurs in both eyes without clear vascular risk factors. Testing may help when features suggest a hereditary optic neuropathy (like Leber hereditary optic neuropathy) or a thrombophilia that raises clot risk. Results can guide prevention, monitoring, and family counseling.
Diagnosis
You might notice sudden, painless blurring or a shadow in one eye, often first thing in the morning, that makes reading or recognizing faces harder. Doctors usually begin by asking about the timing of vision changes and checking each eye carefully. The diagnosis of anterior ischemic optic neuropathy often relies on what the eye looks like during an exam plus tests that rule out other causes, especially inflammation of the arteries. Because symptoms can overlap with other eye or brain conditions, several steps work together to give a clear answer.
Your eye specialist asks when and how the vision loss started and whether it was painful. They’ll ask about earlier episodes, scalp or jaw pain, headache, or weight loss that could suggest inflamed arteries. They also review vascular risks such as high blood pressure, diabetes, or sleep apnea.
Each eye is tested for clarity of vision using a chart. Changes can range from mild blur to significant loss. Comparing eyes helps show if only one eye is affected.
Simple color plates check how well each eye sees color. People with anterior ischemic optic neuropathy may have reduced color sensitivity in the affected eye. This helps distinguish optic nerve problems from issues in the eye’s lens or retina.
The doctor looks for a weaker light response in the affected eye, called a relative afferent pupillary defect. This is a common feature when the optic nerve is injured. It supports the diagnosis alongside other findings.
Stages of Anterior ischemic optic neuropathy
Anterior ischemic optic neuropathy does not have defined progression stages. It usually occurs as a sudden drop in vision over hours to a few days rather than a slow, step-by-step change, and then tends to stabilize; the other eye can be affected at a separate time. People often notice early symptoms of anterior ischemic optic neuropathy as sudden, painless vision loss or a dark curtain over part of the view. Different tests may be suggested to help confirm the diagnosis—this often includes a careful eye exam and visual field testing, blood tests to look for inflammation linked to giant cell arteritis, and sometimes a small artery biopsy if the arteritic form is suspected.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, and the answer with anterior ischemic optic neuropathy (AION) depends on the type and how quickly it’s treated. Vision loss often appears suddenly in one eye, usually without pain, and stabilizes over days to weeks. Some people regain a small amount of clarity over the first few months, but large improvements are uncommon once the optic nerve fibers are damaged. Doctors call this the prognosis—a medical word for likely outcomes. The risk to the other eye is real but varies by cause: in non-arteritic AION, about 15–20% may have the second eye affected over 5 years, while in arteritic AION from giant cell arteritis, the second eye can be threatened within days without prompt steroids.
Even though it can feel overwhelming, early care can make a real difference in preventing further vision loss in arteritic AION; high-dose steroids started right away can protect the fellow eye and reduce systemic complications like stroke. For non-arteritic AION, there’s no proven treatment to reverse damage, but managing blood pressure swings, sleep apnea, diabetes, and cholesterol may lower the chance of another event. People living with AION often adapt daily routines with contrast-enhancing lighting, magnifiers, and orientation training, and many continue to work and drive if the other eye remains strong and local rules allow. Mortality is not directly driven by AION itself, but the arteritic form is linked to an inflammatory artery disease that carries higher risks for heart and brain events if untreated, so fast diagnosis protects both vision and overall health.
Understanding the prognosis can guide planning and support. Ask about early symptoms of anterior ischemic optic neuropathy in the other eye—such as a sudden dark patch, dimming, or color fading—and what to do if they appear. With ongoing care, many people maintain independence by combining medical follow-up, low-vision tools, and practical adjustments at home and work. Talk with your doctor about what your personal outlook might look like, including your specific risk for the second eye and how to lower it.
Long-term effects
Vision after anterior ischemic optic neuropathy often stabilizes after the first few weeks, but what remains can be lifelong. It typically leaves gaps in the visual field and reduces how well you see contrast and color, which can affect reading, driving, and getting around safely. Some people regain a little clarity over months, while others notice little change. Doctors may track these changes over years to see how both eyes are doing.
AION can leave lasting blind spots or blurred areas that do not fully recover. The remaining vision often feels less sharp even with new glasses.
Missing areas to one side or above/below are common and can make it easy to miss steps or bump into objects. You may not notice the gap until you test each eye separately.
Fine print, faces in dim light, or gray-on-gray details can be hard to make out. This contrast loss can be more limiting than a change in the eye chart line.
Colors may look washed out or less vibrant in the affected eye. Subtle shades like blues and greens can be harder to tell apart.
How is it to live with Anterior ischemic optic neuropathy?
Living with anterior ischemic optic neuropathy can feel like a sudden dimming or missing patch in your vision that doesn’t fully return, making reading, recognizing faces, or navigating unfamiliar places more tiring and sometimes unsafe, especially in low light. Many find that practical tweaks—good lighting, high‑contrast settings, large‑print or text‑to‑speech tools, and orientation training—restore confidence and independence, while regular follow‑up helps protect the other eye and manage cardiovascular risk factors. Loved ones may notice you need more time for visual tasks or prefer specific setups at home, and their patience with small adjustments—clear walkways, consistent lighting, verbal cues—can make a big difference. With low‑vision rehabilitation and support, many rebuild routines and stay active, even if the way they approach visual tasks changes.
Treatment and drugs
Treatment for anterior ischemic optic neuropathy (AION) focuses on protecting the other eye, managing risk factors, and addressing any underlying causes, because there’s no proven way to reverse vision already lost. Doctors act quickly to rule out arteritis (often giant cell arteritis); if that’s suspected, high-dose corticosteroids are started right away to prevent further vision loss. For non-arteritic AION, care centers on optimizing blood flow and nerve health: managing blood pressure (especially avoiding very low night-time readings), treating sleep apnea, stopping smoking, and controlling diabetes and cholesterol. You might picture this as a team effort between you and your doctor, sometimes including a rheumatologist or cardiologist to fine-tune systemic treatment. Low-vision rehabilitation, protective eyewear, and driving/workplace adjustments can help daily function, and your doctor can help weigh the pros and cons of each option.
Non-drug treatment
Vision changes from anterior ischemic optic neuropathy can affect reading, depth perception, and everyday tasks like walking down stairs or recognizing faces in dim light. Alongside medicines, non-drug therapies can improve safety, independence, and quality of life. Because early symptoms of anterior ischemic optic neuropathy can appear suddenly, practical support started early often helps you adapt more smoothly. These approaches also focus on protecting overall eye and heart health to reduce future risk.
Build heart-healthy habits with regular activity, balanced meals, and not smoking. Work with your clinicians to avoid big overnight blood pressure drops that can strain the optic nerve.
If you snore or feel unrefreshed, a sleep study may check for apnea. Treating apnea with CPAP or similar devices can lower strain on the optic nerve and may help protect the fellow eye.
Stopping smoking improves blood flow to the optic nerve. Quitting also lowers your risk of stroke and heart disease, which often travel with this condition.
Regular moderate exercise and a Mediterranean-style eating pattern support healthy circulation. This can help reduce risks linked to anterior ischemic optic neuropathy.
Your genes may have an impact on how drugs work for you
Some people process AION medications differently because gene variants change how fast the liver activates or clears drugs, which can alter benefit and side effects. When treatment choices exist, clinicians may use family history or pharmacogenetic tests to guide dosing.
Pharmacological treatments
Treatment for anterior ischemic optic neuropathy (AION) depends on whether it’s caused by giant cell arteritis or not. When inflammation of blood vessels is the driver, fast steroid treatment can help protect the other eye; when it’s the more common non-arteritic type, no medicine has clearly been shown to restore vision. Because early symptoms of anterior ischemic optic neuropathy from giant cell arteritis can threaten both eyes, urgent evaluation and treatment matter. Not everyone responds to the same medication in the same way.
High-dose intravenous methylprednisolone followed by a tapering course of oral prednisone is the standard for AION from giant cell arteritis. Starting promptly can lower the chance of vision loss in the other eye. Your team will monitor blood tests and side effects closely.
This medicine can be added in giant cell arteritis to help keep the disease quiet after the acute phase. It can reduce steroid exposure and lower relapse risk. It is given by injection or infusion under specialist care.
Some clinicians may consider a short course very early in non-arteritic AION, but evidence for improving vision is mixed. Potential benefits must be balanced with side effects like blood sugar rise, mood changes, and bone loss. Decisions are individualized after eye and medical evaluation.
Aspirin or clopidogrel is often used to reduce stroke and heart-attack risk after AION, especially if you have vascular risk factors. These drugs have not been proven to restore vision in AION. Discuss the best option and dose for you with your doctor.
Genetic influences
For most people with anterior ischemic optic neuropathy (AION), genetics are not the main driver. In the non-arteritic form, inherited traits like a small, crowded optic nerve and shared family risks such as high blood pressure or sleep apnea can raise susceptibility, but the vision loss event is usually triggered by changes in blood flow. In the arteritic form linked to giant cell arteritis, certain immune‑system gene patterns (such as some HLA types) can increase the chance of the inflammation that affects the optic nerve. Having a genetic risk is not the same as having the disease itself. There is no standard genetic test for anterior ischemic optic neuropathy, and testing is not typically helpful unless your doctor suspects another inherited optic nerve condition. Still, if several relatives have had giant cell arteritis or sudden, similar vision loss, sharing that history can help your care team tailor prevention and monitoring.
Is Anterior ischemic optic neuropathy genetic?
Genetics play a modest role in anterior ischemic optic neuropathy. Most cases relate to vascular risk factors, but inherited traits like crowded optic discs or blood clotting tendencies can increase susceptibility. Rarely, mitochondrial or small-vessel gene variants may contribute.
Pharmacogenetics—how genetics influence drug effects
Treatment choices in anterior ischemic optic neuropathy depend on the cause: urgent high‑dose steroids for the arteritic form linked to giant cell arteritis, and risk‑reduction medicines such as antiplatelets and statins for the nonarteritic form. Genes can shape how you respond to some of these medicines—differences in a liver enzyme may limit how well clopidogrel works, and changes in a liver transporter can raise the chance of statin muscle aches. Genetic testing can sometimes identify how your body activates clopidogrel or handles statins, which can help your doctor choose an alternative drug or dose that fits you better. For the steroids used to treat arteritic anterior ischemic optic neuropathy, there isn’t a standard genetic test to guide dosing; doctors rely on close monitoring and tapering based on symptoms and lab results. If medications for anterior ischemic optic neuropathy include immunosuppressive therapy for giant cell arteritis, there are no widely accepted genetic markers that predict who will respond. Your overall health, age, and other prescriptions also influence drug effects, so any genetic insight is used alongside clinical judgment.
Interactions with other conditions
People living with Anterior ischemic optic neuropathy (AION) often also have conditions that affect blood vessels, like high blood pressure, diabetes, high cholesterol, or heart disease; these can raise the chance of AION and may influence how vision changes over time. Sleep apnea is a common partner condition—drops in oxygen and blood pressure during the night can set the stage for vision loss on waking, and treating sleep apnea (for example, with CPAP) may lower the risk to the other eye. Doctors call it a “comorbidity” when two conditions occur together, and with AION the most important ones usually involve circulation and inflammation. In older adults, giant cell arteritis (temporal arteritis) is a critical overlap; its artery inflammation can directly cause AION and threatens vision in both eyes without urgent treatment. Conditions that reduce oxygen delivery, such as significant anemia or advanced kidney disease, may also make AION more likely or more severe. If you live with sleep apnea, diabetes, or suspected arteritis, tell your eye and primary care teams about any early symptoms of Anterior ischemic optic neuropathy, including sudden painless vision loss—coordinated care can help protect your sight.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden vision dimming in one eye after an illness, a restless night, or waking in the morning to find a shadow blocking part of their view. Doctors noticed that for many, this loss came without pain, and that colors looked washed out on the affected side. Over time, careful drawings of the blind spot pattern and notes about a pale, swollen optic nerve at the back of the eye helped link these experiences to a circulation problem in the optic nerve rather than in the eye itself.
First described in the medical literature as a distinct form of “optic nerve stroke,” anterior ischemic optic neuropathy became better defined in the mid–20th century as eye doctors correlated bedside exams with what they saw through the pupil. Early case series separated people with crowded, small optic nerve heads and vascular risk factors from those with inflammation of the arteries supplying the head and eyes. That split—often called non‑arteritic versus arteritic—explained why some people with anterior ischemic optic neuropathy were otherwise well, while others had scalp tenderness, jaw pain when chewing, fatigue, and a high risk of losing vision in the other eye if not treated quickly.
As medical science evolved, fluorescein angiography and later optical coherence tomography allowed clinicians to watch blood flow and tissue swelling in real time, strengthening the idea that interrupted circulation at the front of the optic nerve triggers the event. Pathology studies of temporal artery biopsies in giant cell arteritis clarified the arteritic form, while long-term follow-up studies showed that the non‑arteritic form often stabilizes after the initial drop in sight.
In recent decades, awareness has grown that anterior ischemic optic neuropathy isn’t rare, especially in adults over 50, and that timing matters. Reports drew attention to morning onset, links with low nighttime blood pressure, sleep apnea, diabetes, high blood pressure, and cholesterol, as well as medications or surgeries that can lower blood pressure or cause blood loss. At the same time, researchers mapped out the typical “altitudinal” visual field loss and recognized the role of a “crowded” optic nerve structure as a risk factor, not a cause on its own.
From early theories to modern research, the story of anterior ischemic optic neuropathy continues to be refined by better imaging, large population studies, and collaboration between eye doctors, neurologists, and rheumatologists. Historical differences highlight why today’s care emphasizes urgent evaluation to rule out arteritis, thoughtful management of vascular risks, and realistic counseling about visual recovery. Looking back helps explain current practice: prompt treatment when inflammation of the arteries is suspected, and prevention-focused care when the cause is non‑arteritic.